Shimadzu, an analytical instrument manufacturer, has announced the formation of a partnership with Cure Pharmaceutical Group and CK Sciences to research and develop pharmaceutical cannabis-based products. The three organizations entered a collaborative agreement with the goal of researching and developing products, then moving them through clinical trials using FDA guidelines.

The primary goal of this partnership will be researching and profiling the synergistic effects of the cannabinoids and terpenes, called the Entourage Effect.

Shimadzu has worked extensively with cannabis laboratories throughout the country in refining methods and improving analytical chemistry in the space. Shimadzu powers EVIO Labs Florida with over $1.2 million in the latest testing instrumentation.

Shimadzu has launched their Cannabis Analyzer for Potency, a high-performance liquid chromatograph (HPLC) designed specifically for quantitative determination of cannabinoid content. The organizations in the partnership will be using that instrument, in addition to a headspace Gas Chromatograph Mass Spectrometer (GCMS) for terpene profiling. Both Cure and CK will use the instruments to generate data, with the goal to validate cannabis as a viable pharmaceutical treatment